Merrimack Pharmaceuticals Inc
General ticker "MACK" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $189.8M
Merrimack Pharmaceuticals Inc follows the US Stock Market performance with the rate: 50.4%.
Estimated limits based on current volatility of 0.1%: low 15.13$, high 15.17$
Factors to consider:
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term predictions were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 predicted range: [8.88$, 18.63$]
- 2024-12-30 to 2025-12-30 predicted range: [8.73$, 18.10$]
Financial Metrics affecting the MACK estimates:
- Negative: Non-GAAP EPS of -0.08 <= 0.08
- Negative: Operating Income to Revenue ratio of -1.00 <= 0.01
- Negative: Operating Cash Flow per share of -0.11 <= 0.20
- Negative: negative Net Income
- Negative: Industry Operating Cash Flow per share (median) of -1.49 <= 0.29
- Negative: Industry Earnings per Price (median) of -0.28 <= 0.01
Short-term MACK quotes
Long-term MACK plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $2.47MM | $1.73MM | $2.18MM |
| Operating Income | $-2.47MM | $-1.73MM | $-2.18MM |
| Non-Operating Income | $0.02MM | $0.19MM | $1.01MM |
| Income(Loss) | $-2.45MM | $-1.54MM | $-1.17MM |
| Taxes | $0.00MM | $0.00MM | $0.01MM |
| Profit(Loss) | $-2.46MM | $-1.54MM | $-1.18MM |
| Stockholders Equity | $14.19MM | $19.25MM | $18.75MM |
| Assets | $14.75MM | $19.84MM | $19.19MM |
| Operating Cash Flow | $-0.22MM | $-1.74MM | $-1.52MM |
| Investing Cash Flow | $0.14MM | $0.45MM | $-12.45MM |
| Financing Cash Flow | $0.24MM | $6.53MM | $0.52MM |
| Earnings Per Share* | $-0.18 | $-0.11 | $-0.08 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.